therapies targeting conditions such as retinitis pigmentosa, Stargardt’s disease, and geographic atrophy, with programs at various stages from discovery to clinical development. Its work centers on translating gene therapy research into treatments that address inherited retinal diseases and other degenerative eye conditions. The organization is led by a team with experience in biotechnology, ophthalmology, and gene therapy development, supporting research, clinical operations, and program management activities.